Add
PLX to Portfolio
Set Alert
Email to a
Friend
| |||
|
|
Quotes & Info
|
| PLX > SEC Filings for PLX > Form 8-K on 22-Jun-2012 | All Recent SEC Filings |
22-Jun-2012
Regulation FD Disclosure, Other Events, Financial Statements and E
On June 22, 2012, Protalix BioTherapeutics, Inc. (the "Company") issued a press release announcing that the Company has scheduled a conference call and webcast for Friday, June 22 at 9:00 AM EDT to review the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use ("CHMP") opinion for taliglucerase alfa (ELELYSO™), an enzyme replacement therapy for the treatment of Gaucher disease. A copy of the press release is furnished as Exhibit 99.1.
The information contained in Item 7.01 of this report and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
On June 22, 2012, the Company issued a press release announcing that the CHMP has issued an Opinion recommending against the marketing authorization of taliglucerase alfa (ELELYSO™). A copy of the press release is filed as Exhibit 99.2.
(d) Exhibits
99.1 Press release dated June 22, 2012.
99.2 Press release dated June 22, 2012.
|
|